Menu
In a SENS released by the JSE yesterday, the Board Of Cilo Cybin announced a delay in plans to list the first Cannabis-focused SPAC on the Main Board of the JSE.
The reason for my letter is to express my utmost gratitude to you personally for your support and participation in the IPO. We are truly humbled and overwhelmed by the public’s response. The JSE minimum capital requirement for a listing, as a special purpose acquisition company (“SPAC”), has not been met within the set timeframe and the listing on the JSE as a SPAC cannot proceed as yet.
New developments are in the pipeline, and we have determined that the need to respond rapidly to take full advantage of these opportunities has to be prioritised. It is therefore in the best interest of the Company to focus on its growth initiatives, and thus postpone listing to a later date.
The process to refund your investment is as follows:
Thank you once again for your kind interest and belief in Cilo Cybin’s vision. My sincere wish is to invite you back on board again soon to join us on our ground-breaking journey.
“One needs to be able to celebrate your losses as well as your successes. Sometimes what appears to be a loss, turns out to be a success.”
With Kind Regards
Gabriel Theron
To obtain the refund forms please send an email to ipo@cilocybin.com and we will send you the necessary documentation back.
Cilo Cybin Holdings Limited, is a South African incorporated legal entity that is in the process of an Initial Public Offering (IPO) on the Johannesburg Stock Exchange. The public is now able to invest in us.
This page is to provide a high level overview of Cilo Cybin Holdings, as well as more information on the Special Purpose Acquisition Company (SPAC).
You are able to view all the documents that is relevant to the IPO here, or just have a look at the teaser summary.
Please book your slot for the in-person presentation at the JSE by following the link below:
Wednesday 26 October 2022
(In person) 17:30 for 18:00
You can invest in Cilo Cybin Holdings for as little as R1000, today. We have specifically taken this approach as we would like to build an inclusive company, that welcomes everyone.
Follow these easy 5 steps…
Central Securities Depository Participant (CSDP) A CSDP performs custodian and settlement duties for non-controlled clients and JSE brokers (proprietary and controlled clients’ nets) who hold their custody accounts with the CSDPs.
If you do not have a CSDP account, you can still invest, the JSE Investor Services will assist you to get a CSDP account after investment.
Yes, we are open to accept international payments. Investors can make use of the same banking details and use the SWIFT code below:
FNB Swift code: FIRNZAJJ
Sponsor
Independent Reporting Accountants
Independent Auditors
Company Secretary
Company Legal Advisor
Transfer Secretaries
Banker
Escrow Agent
Communications Advisor
Dea-Ru
Mazars
Mazars
Mashobane
Werksmans
JSE Investor Services
FNB
RMB
Mortimer Harvey
The Company will combine businesses within the Biohacking, Biotech, and Pharmaceutical methodologies to deliver a holistic and legalised solution, through Artificial Intelligence, that will enable its customers’ insights into their health, performance, and longevity, that they never had before.
We believe the world is entering a new era of personalised healthcare, a world in which each person’s health and wellbeing will require bespoke, individualised and intelligently targeted interventions.
Cilo Cybin is ready and able to successfully propel its product and service offering to a world that continues to hope and strive for better health, performance, and longevity.
In terms of the JSE Listings Requirements, the Company must Complete an acquisition of Viable Assets within the Initial Period. The acquisition of Viable Assets must be approved by a majority of disinterested Directors and by an ordinary resolution of Shareholders at a general meeting.
The Viable Assets, which will be managed by the Company following their acquisition, may include direct or indirect investments in projects and/or businesses whose purpose is to cultivate, manufacture, analyse, distribute, or retail in any of the pharmaceutical, biotech or biohacking industries, and in respect of which the Board has identified an opportunity to enhance the combined offering of the complete service and product offering of the Company with the goal to improve profitability, thereby maximising Shareholder return.
While the Company’s efforts in identifying prospective Viable Assets will not be limited to a particular industry or geographic region, locally or internationally, the Company expects to also acquire a controlling interest in a Company or business in the Cannabis industry.
The Company will combine businesses within the Biohacking, Biotech, and Pharmaceutical methodologies to deliver a holistic and legalized solution that will enable its customers’ insights into their health, performance, and longevity, that they never had before.
What is Biotech & Pharmaceutical:
Biotechnology and pharmaceutical companies both produce medicines, but the medicines made by biotechnology companies are derived from living organisms while those made by pharmaceutical companies generally have a chemical basis.
What is Biohacking:
Biohacking is the constant pursuit of better health, performance, and longevity using technologies, apps, devices, and supplementation
Data is the future of medical care and preventative healthcare. Having access to patient’s genetic, lab and symptom data can be the start of heath discoveries that we can only dream of today.
Today we can easily assist certain genetic mutations with health supplements, this is considered to be mainstream, tomorrow we can alter genetics permanently.
Register here in order to be the first to receive access to pre order products.